• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)
Conclusion Rheumatic heart disease patients were young, predominantly female, and had high prevalence of major cardiovascular complications. There is suboptimal utilization of secondary antibiotic prophylaxis, oral anti-coagulation, and contraception, and variations in the use of percutaneous and surgical interventions by country income level.
Source: European Heart Journal - May 7, 2015 Category: Cardiology Authors: Zuhlke, L., Engel, M. E., Karthikeyan, G., Rangarajan, S., Mackie, P., Cupido, B., Mauff, K., Islam, S., Joachim, A., Daniels, R., Francis, V., Ogendo, S., Gitura, B., Mondo, C., Okello, E., Lwabi, P., Al-Kebsi, M. M., Hugo-Hamman, C., Sheta, S. S., Haile Tags: Valvular heart disease Source Type: research

Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system
Conclusions Transcatheter tricuspid valve repair by use of interventional edge-to-edge repair with the MitraClip system was feasible, and safe in three consecutive patients. Reduction of tricuspid insufficiency associates with relief of clinical symptoms for right heart failure. This strategy seems a promising treatment option for patients at prohibitive surgical risk.
Source: European Heart Journal - March 7, 2016 Category: Cardiology Authors: Hammerstingl, C., Schueler, R., Malasa, M., Werner, N., Nickenig, G. Tags: EHJ BRIEF COMMUNICATION Source Type: research

Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study
ConclusionFive-year results in real-world, elderly, high-risk patients undergoing TAVI with a self-expanding bioprosthesis provided evidence for continued valve durability with low rates of reinterventions and haemodynamic valve dysfunction.Trial registrationClinicalTrials.gov, NCT01074658.
Source: European Heart Journal - June 13, 2017 Category: Cardiology Source Type: research

Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement
ConclusionsTransthyretin cardiac amyloidosis is prevalent in 16% of patients with severe calcific AS undergoing TAVR and is associated with a severe AS phenotype of low-flow low-gradient with mildly reduced ejection fraction. Average tissue Doppler mitral annular S ’ of <  6 cm/s may be a sensitive measure that should prompt a confirmatory99mTc-PYP scan and subsequent testing for ATTR-CA. Prospective assessment of outcomes after TAVR is needed in patients with and without ATTR-CA.
Source: European Heart Journal - August 1, 2017 Category: Cardiology Source Type: research

Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience
ConclusionTranscatheter mitral valve implantation using balloon-expandable valves in selected patients with bioprosthesis or annuloplasty failure or severe MAC was associated with a low rate of peri-procedural complications and acceptable long-term outcomes.
Source: European Heart Journal - May 19, 2018 Category: Cardiology Source Type: research

Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis
Conclusion  Compared with SAVR, TAVI is associated with reduction in all-cause mortality and stroke up to 2  years irrespective of baseline surgical risk and type of THV system.
Source: European Heart Journal - April 23, 2019 Category: Cardiology Source Type: research

Variable rate of stroke after transcatheter aortic valve replacement with self-expandable valves: more doubts than certainties
This commentary refers to ‘Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial’ by H. Thieleet al., 2020;41:1890 –1899.
Source: European Heart Journal - August 18, 2020 Category: Cardiology Source Type: research

Stroke rates after transcatheter aortic valve replacement: does valve choice play a role?
This commentary refers to ‘Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial’, by H. Thieleet al., 2020;41:1890 –1899.
Source: European Heart Journal - August 18, 2020 Category: Cardiology Source Type: research

Pages: 1  2